Hydrus Microstent for Refractory Open-Angle Glaucoma
Launched by IVANTIS, INC. · Aug 28, 2017
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Participants will attend a screening visit, a baseline visit, a surgery visit, and 8 post-operative visits (Day 1, Day 7, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12), for a total individual duration of approximately 14 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Open-angle glaucoma with optic nerve pathology;
- • Best Corrected Visual Acuity of 20/80 or better in study eye;
- • Refractory glaucoma;
- • Other protocol-specified inclusion criteria may apply.
- Exclusion Criteria:
- • Secondary glaucoma other than pseudoexfoliative and pigmentary glaucoma;
- • Acute angle closure, chronic angle closure, or congenial, malignant, or developmental glaucoma;
- • Pre-perimetric glaucoma;
- • Ocular hypertension
- • Shallow or flat anterior chamber;
- • Other protocol-specified exclusion criteria may apply.
About Ivantis, Inc.
Ivantis, Inc. is a pioneering medical device company dedicated to transforming the treatment of glaucoma through innovative technologies. Focused on developing minimally invasive surgical solutions, Ivantis aims to enhance patient outcomes and improve quality of life for individuals suffering from this progressive eye disease. With a commitment to rigorous clinical research and collaboration with healthcare professionals, Ivantis is at the forefront of advancing glaucoma care, striving to provide effective, safe, and patient-centered therapies that address the unmet needs within the ophthalmology field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zaragoza, , Spain
Dallas, Texas, United States
Fort Worth, Texas, United States
Alexandria, Louisiana, United States
Austin, Texas, United States
Makati City, , Philippines
Manchester, , United Kingdom
Cranberry Township, Pennsylvania, United States
Fayetteville, Arkansas, United States
Sacramento, California, United States
El Paso, Texas, United States
Fort Collins, Colorado, United States
Kenosha, Wisconsin, United States
Ocala, Florida, United States
Venice, Florida, United States
Overland Park, Kansas, United States
Saint Louis, Missouri, United States
Houston, Texas, United States
San Antonio, Texas, United States
Barranquilla, , Colombia
Patients applied
Trial Officials
Clinical Project Lead, CRD Surgical
Study Director
Alcon Research, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials